Development of a Recombinant Based ELISA using Specific Antibodies to F Protein in HCV Chronically Infected Patients-A Seroprevalence Study

Hashempour, Tayebeh; Ajorloo, Mehdi; Bamdad, Taravat; Merat, Shahin; Zaer-Rezaee, Hanieh; Fakharzadeh, Elham; Asadi, R; Zamini, Hedye; Teimouri, AA

doi:10.21859/isv.4.1.1

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HCV core-1a cDNA sequences obtained from a plasmid (kindly provided by Dr. M Baril, departement of biochemistry, university of Montreal, Canada; based on the protocol of Baril et al 2005) was used as the template for the amplification of core+1 gene as described elsewhere (7). Briefly, the cDNA fragment of the HCV core+1 protein coding sequence was achieved by +1/-1 frame-shifting artificially introduced at codon 31 of the core protein-coding sequence using the following designspecific primers:…”

Section: Recombinant Core+1 Production Purification Western Blottinmentioning

confidence: 99%

“…HCV is one of the leading causes of persistent infection in humans that can predispose to liver fibrosis and cirrhosis. There are some reports indicating that chronic hepatitis C (CHC) infection is strongly associated with hepatocellular carcinoma (HCC) (3)(4)(5)(6)(7)(8)(9). There is neither effective vaccine for immunization, nor a broadly effective treatment for HCV infection (3).Among different factors associated with chronic HCV infection, alternate reading frame protein (ARFP) or core+1 protein is one the newest ones that can promote persistent infection (10)(11)(12).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Hashempoor¹,

Alborzi²,

Moayedi³

et al. 2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

Background: Hepatitis C virus (HCV) causes one of the major chronic liver diseases (CLD). HCV-core encoding sequence possesses an overlapping open reading frame (ORF) that expresses a protein called F or core+1. Objectives: The current study aimed at assessing the presence and titer of anti-core+1 antibody (Ab) in 70 Iranian patients infected with HCV-1a, responder and non-responder groups, under combination therapy with pegylated interferon-α (PegIFN-α) plus ribavirin (RBV) using an enzyme-linked immunosorbent assay (ELISA). Methods: In the current cohort study, HCV-1a core+1 gene was amplified and cloned into vector followed by expressing in Escherichia coli and then, purified by ion exchange chromatography. The antibody titer of patients was evaluated before, during (12, 24, and 48 weeks), and 6 months after the end of therapy (ETR). Results: The seroprevalence of anti-core+1 Ab was 75.7% in pretreatment sera. The combination therapy could induce a decline in the level of anti-core+1 Ab in both groups of responders and non-responders. These changes were significant only in the responders (P = 0.003). The seroprevalence of anti-core+1 Ab had no correlation with the outcome of treatment. Conclusions: According to the current study results, HCV core+1 protein elicit a specific antibody response other than the anti-core protein antibodies. The current study data also suggested that the level of anti-core+1 antibody might be affected by the combination therapy and associated with sustained virological response (SVR). The data implied that the declining trend of anti-core+1 Abs during the treatment might be an alternative representation of the therapeutic response in Iranian population infected with HCV.

show abstract

Section: Recombinant Core+1 Production Purification Western Blottinmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Hashempoor¹,

Alborzi²,

Moayedi³

et al. 2018

Jundishapur J Microbiol

View full text Add to dashboard Cite

show abstract

“…In addition, coreencoding region of this virus expresses a protein entitled alternative reading frameshift protein (ARFP) or frame-shift protein (F protein) 3,4 . It has been shown that in chronic HCV patients, 82% were positive for anti-F antibodies, showing a significant difference from the healthy individuals 5 . This protein increases the frequency of CD4+CD25+ Treg cells, which may be associated with persistent and chronic infection through subversion of the host immune response 6 F proteins could also enhance liver cell proliferation 7 , which is subsequently associated with the disease progression towards cirrhosis 8 .…”

Section: Introductionmentioning

confidence: 97%

Comparison of biomarkers between genotypes 1a and 3a in hepatitis C virus patients with control group

et al. 2019

View full text Add to dashboard Cite

Introduction: Three percent of people worldwide are infected with Hepatitis C virus (HCV). A few studies have been performed to evaluate the biochemical markers of the disease. In the current study, biochemical markers were evaluated in HCV patients and the control group. Methods: Two sex- and age-matched healthy individuals (n = 100) and HCV positive patients (n = 100) were included (mean age of 20-75, 26.0% females and 74.0% males). Biochemical markers, including liver enzymes (ALT, AST and ALP), lipid profiles (cholesterol, LDL, and HDL) and triglyceride (TG) were investigated in both groups. HCV genotyping was also performed by Polymerase Chain Reaction (PCR) and OHNO methods. Results: The biochemical markers between HCV patients and controls were compared (cholesterol, ALP, AST, ALT, LDL: p = 0.0001, HDL: p = 0.002, TG: p = 0.003), and statistically significant difference was found between two groups. The biochemical markers between HCV patients and the control group in terms of age was compared and no differences was observed (p = 0.741), however, there was a significant difference in sex between HCV patients and control group (26.0% females, 74.0% males in control group, and x% females and y% males in HCV patients) (p = 0.032). The results of HCV genotyping showed that 39 patients were genotype 1a, and 43 patients were genotype 3a, and 1 patient was genotype 2a. Evaluation of biochemical markers in patients with genotype 1a and 3a showed that there were significant differences in cholesterol (p = 0.001), LDL (p = 0.001) and HDL (p= 0.003) levels, but there were no significant differences in liver enzymes and TG levels in both genotypes. Conclusion: In the present study, we found significant difference in biochemical markers between HCV patients and controls. In HCV patients, the biochemical markers were dependent on HCV genotypes, and their levels in genotype 1a were higher than genotype 3a. In conclusion, biochemical markers are one of the most important factors for the identification of treatment.

show abstract

F protein increases CD4+CD25+ T cell population in patients with chronic hepatitis C

Hashempour

Bamdad

Bergamini

et al. 2015

Pathogens and Disease

View full text Add to dashboard Cite

HCV is a global health problem with an estimated 230 million chronically infected people worldwide. It has been reported that a 17-kd protein translated from core-encoding genomic region can contribute to immune-mediated mechanisms associated with the development of the chronic disease. Also, Treg cells can be contributed to an inadequate response against the viruses, leading to chronic infection. Here we evaluated the ability of protein F to modulate the frequency of CD4+CD25+FoxP3+T and IL-10+T cells in patients with chronic HCV infection. F gene was amplified and cloned in the expression vector. The protein was purified and used for stimulation of PBMCs in the HCV chronic patients and the control groups. The frequency of CD4+CD25+FoxP3+ T cell-like populations and IL-10-producing CD4+CD25+ T cells was assessed in the HCV-infected patients and in the healthy controls by flow cytometry, which showed an increase of both CD4+CD25+FoxP3+ T cell-like population and IL-10-producing CD4+CD25+ T cells in the HCV-infected patients positive for anti-F antibody. Our results suggest the potential involvement of F and core antigens in increasing the frequency of CD4+CD25+FoxP3+ T cell-like population and IL-10-producing CD4+CD25+ T cells which may be associated with HCV-persistent infection.

show abstract

Development of a Recombinant Based ELISA using Specific Antibodies to F Protein in HCV Chronically Infected Patients-A Seroprevalence Study

Cited by 4 publications

References 20 publications

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected with Hepatitis C Virus

Comparison of biomarkers between genotypes 1a and 3a in hepatitis C virus patients with control group

F protein increases CD4+CD25+ T cell population in patients with chronic hepatitis C

Contact Info

Product

Resources

About